US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ensysce Biosciences Inc.

3.02

+0.0000

Volume:90.21K

Turnover:275.40K

Market Cap:4.97M

PE:-0.26

High:3.19

Open:3.08

Low:2.98

Close:3.02

Loading ...

Overview Company News Filings

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

ACCESS Newswire

ENSC Continues to Announce Potential Life-Changing Results

Zacks Small Cap Research

Ensysce focused on clinical development milestones for PF614, PF614-MPAR

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Regains Full Compliance With Nasdaq Listing Rules

MT Newswires Live

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences trading halted, news pending

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

BRIEF-Ensysce Biosciences Inc Announces 1-For-15 Reverse Stock Split

Ensysce Biosciences Inc: Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences doses first subjects in PF614-MPAR trial

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate

Simply Wall St.

ENSC Improves Position

Zacks Small Cap Research

Ensysce Biosciences GAAP EPS of $0.07 beats by $0.24

Ensysce Biosciences Q3 2024 GAAP EPS $0.07 Beats $(0.29) Estimate, Sales $3.40M Beat $250.00K Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENSC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENSC\",,,,,undefined,":{"symbol":"ENSC","market":"US","secType":"STK","nameCN":"Ensysce Biosciences Inc.","latestPrice":3.02,"timestamp":1746125940015,"preClose":3.02,"halted":0,"volume":90214,"delay":0,"floatShares":1136100,"shares":1644728,"eps":-11.448165,"marketStatus":"Trading","change":0,"latestTime":"05-01 14:59:37 EDT","open":3.08,"high":3.1905,"low":2.98,"amount":275395.6823876,"amplitude":0.069702,"askPrice":3.05,"askSize":100,"bidPrice":2.98,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.448165,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.02,"preHourTrading":{"tag":"盘前","latestPrice":2.9904,"preClose":3.02,"latestTime":"09:29 EDT","volume":2119,"amount":6449.866022599999,"timestamp":1746106187023},"postHourTrading":{"tag":"盘后","latestPrice":3.14,"preClose":3.02,"latestTime":"19:57 EDT","volume":9403,"amount":28409.0827,"timestamp":1746057476839},"volumeRatio":0.152097,"impliedVol":3.1521,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENSC\",,,,,undefined,":{"symbol":"ENSC","floatShares":1136100,"roa":"-101.29%","roe":"-585.41%","lyrEps":-11.448165,"volumeRatio":0.152097,"shares":1644728,"dividePrice":0,"high":3.1905,"amplitude":0.069702,"preClose":3.02,"low":2.98,"week52Low":1.62,"pbRate":"1.34","psRate":"0.95","week52High":14.67,"institutionHeld":0,"latestPrice":3.02,"eps":-11.448165,"divideRate":0,"volume":90214,"delay":0,"ttmEps":-11.448165,"open":3.08,"prevYearClose":8.14,"prevWeekClose":3.29,"prevMonthClose":3.02,"prevQuarterClose":2.56,"fiveDayClose":3.31,"twentyDayClose":2.64,"sixtyDayClose":6.29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENSC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2505974788","title":"Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2505974788","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505974788?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is CoAdministered with Nafamostat as a Combination of Immediate Release Solution and Extended Release Capsule Formulations  in Healthy Subjects,' was designed to evaluate the full dosage range of PF614-MPAR, study potential food effects, and to conduct a multiple ascending dose study with the final PF614-MPAR combination. In 2024, PF614-MPAR received Breakthrough Therapy designation from the U.S. Food and Drug Administ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-positive-interim-130000627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2505720254","title":"ENSC Continues to Announce Potential Life-Changing Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2505720254","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505720254?lang=en_us&edition=fundamental","pubTime":"2025-01-22 19:06","pubTimestamp":1737543960,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths from opioid overdoses and there are also exponentially more lives negatively impacted by opioid abuse.Testing on these treatments continues and the company recently announced encouraging interim results from its second clinical trial evaluating PF614-MPAR for overdose protection. The headline from the release is that “The subjects receiving the MPAR product had a significantly lower total maximum blood concentration of oxycodone compared to PF614 alone, an indication of overdose protection. This news continues a string of positive test results that continue to illustrate the potential of ENSC pain treatments to be game changers. The company also commented that there were no adverse events reported during testin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensc-continues-announce-potential-life-110600665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2501093727","title":"Ensysce focused on clinical development milestones for PF614, PF614-MPAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2501093727","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501093727?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:51","pubTimestamp":1736344283,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) issued a letter to shareholders from CEO Lynn Kirkpatrick, which read, in part, “2024 was underscored by outstanding pro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-focused-on-clinical-development-milestones-for-pf614-pf614-mpar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-focused-on-clinical-development-milestones-for-pf614-pf614-mpar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2501772013","title":"Ensysce Biosciences Issues Annual Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2501772013","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501772013?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to commence 1H 2025 ~SAN DIEGO, CA / ACCESSWIRE / January 8, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.In 2024, we made significant progress toward our development milestones for PF614. Early in 2024, we completed a regulatory End of Phase 2 meeting with the FDA, an important discussion about our program which provided feedback","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-issues-annual-shareholder-130000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","BK4139","CTS","BK4145","IE0031619046.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","ENSC"],"gpt_icon":0},{"id":"2493760368","title":"Ensysce Biosciences Regains Full Compliance With Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2493760368","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493760368?lang=en_us&edition=fundamental","pubTime":"2024-12-24 00:30","pubTimestamp":1734971426,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  said Monday it has regained compliance with Nasdaq's minimum stock price requirement for continued listing.The pharmaceutical company said that since it had earlier regained compliance the exchange's stockholders' equity rule, it has now met all requirements outlined in a recent hearings panel decision, so its stock will continue trading on the Nasdaq Capital Market.Price: 8.29, Change: +0.19, Percent Change: +2.35","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","NQmain","BK4139","ENSC","LU2095319765.USD",".IXIC","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4588","BK4112","NDAQ"],"gpt_icon":0},{"id":"2493264769","title":"Ensysce Biosciences Regains Full Compliance with Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2493264769","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493264769?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:00","pubTimestamp":1734958800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December 20, 2024, it received notice from The Nasdaq Stock Market LLC  that the Company has demonstrated compliance with the minimum bid price requirement in Listing Rule 5550. Ensysce had previously regained compliance with the stockholders' equity requirement in Listing Rule 5550. As a result, the Company has met all requirements outlined in the Nasdaq Hearings Panel decision dated November 5, 2024, and Ensysce common stock will continue trading on The Nasdaq Capital Market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-regains-full-compliance-130000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","USAW.SI","LU2095319765.USD","IE00BGHQF748.EUR","QLD","TQQQ","IE00B64PRP62.GBP","ENSC","IE00BKPKM429.USD","BK4139","BK4112","PSQ","NVIW.SI","IE00B3QW5Z07.USD","TSYW.SI","QID","BK4585","USJW.SI","LU2210149790.SGD","NQmain","SQQQ","BK4588","LU2210150020.SGD","MNQmain",".IXIC"],"gpt_icon":1},{"id":"2490130500","title":"Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2490130500","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490130500?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835600,"startTime":"0","endTime":"0","summary":"~ Supply Chain Now Fully Secure for PF614-MPAR ~SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt of commitment of future supply of GMP nafamostat, a critical component of PF614-MPAR. This agreement fully secures the supply chain and allows Ensysce to reference the nafamostat Drug Master File of Aurore Life Sciences, a renowned specialty drug manufacturer.About Aurore Life SciencesAurore Life Sciences, established in 2017, is a leading manufacturer of Active Pharmaceutical Ingredients  and intermediates, offering high-quality, affordable bulk drug solutions to over 55 countries worldwide. With a pure-play focus on APIs and intermediates, Aurore is a fully backward-integrated pharmaceutical company dedicated to delivering to all regulated markets globally.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-commercial-supplier-130000937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2489444819","title":"Ensysce Biosciences trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2489444819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489444819?lang=en_us&edition=fundamental","pubTime":"2024-12-06 08:50","pubTimestamp":1733446207,"startTime":"0","endTime":"0","summary":"19:50 EST Ensysce Biosciences (ENSC) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-trading-halted-news-pending?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2488195979","title":"Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR","url":"https://stock-news.laohu8.com/highlight/detail?id=2488195979","media":"ACCESSWIRE","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488195979?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:00","pubTimestamp":1733317200,"startTime":"0","endTime":"0","summary":"~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the initiation of a strategic partnership with a leading specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR drug products.This collaboration underscores a shared commitment to achieving swift regulatory approval and efficient development of the Company's innovative drug products. The strategic partnership will provide Ensysce with the clinical trial material, drug products for regulatory submissions, and initial commercial batches of PF614 and PF614-MPAR. The partner's services will also encompass the complete manufacturing process, including packaging, labeling, and shipment of the products, ensuring a se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-strategic-partnership-130000121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0149725797.USD","LU0267386448.USD","LU1363072403.SGD","CMC","LU0170899867.USD","LU0882574139.USD","LU0971096721.USD","IE00BZ1G4Q59.USD","ENSC","IE00B1BXHZ80.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","BK4006","BK4139"],"gpt_icon":0},{"id":"2488397049","title":"BRIEF-Ensysce Biosciences Inc Announces 1-For-15 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2488397049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488397049?lang=en_us&edition=fundamental","pubTime":"2024-12-04 06:51","pubTimestamp":1733266297,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - Ensysce Biosciences Inc   :   * ENSYSCE BIOSCIENCES INC: ANNOUNCES 1-FOR-15 REVERSE STOCK SPLITSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2488028976","title":"Ensysce Biosciences Inc: Announces 1-for-15 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2488028976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488028976?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:17","pubTimestamp":1733260639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nFWN3N40LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2488979566","title":"Ensysce Biosciences Announces 1-for-15 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2488979566","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488979566?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:15","pubTimestamp":1733260500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on Friday, December 6, 2024, effective at 12:01 a.m. Eastern Time, it will implement a 1-for-15 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on December 6, 2024, under its current trading symbol \"ENSC\". The new CUSIP number of the Company's common stock following the reverse stock split will be 293602 504.Ensysce Biosciences is a clinical stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection  and Multi-Pill Abuse Resistance  platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ens","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-announces-1-15-211500699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2486008728","title":"Ensysce Biosciences doses first subjects in PF614-MPAR trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2486008728","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486008728?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:26","pubTimestamp":1732627571,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) has treated its first group of subjects in the PF614-MPAR-102 study. PF614-MPAR received Breakthrough Therapy designatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-doses-first-subjects-in-pf614-mpar-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-doses-first-subjects-in-pf614-mpar-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2486704270","title":"Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2486704270","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486704270?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has treated its first group of subjects in the PF614-MPAR-102 study. PF614-MPAR received Breakthrough Therapy designation from the U.S. Food and Drug Administration  and had its development bolstered by the recent $14 million multi-year award from the National Institute on Drug Abuse .Ensysce Biosciences is a clinical stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection  and Multi-Pill Abuse Resistance  platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-completes-significant-milestone-130000103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2483536488","title":"Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483536488","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483536488?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:00","pubTimestamp":1731708046,"startTime":"0","endTime":"0","summary":"* Ensysce Biosciences Inc    reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC"],"gpt_icon":0},{"id":"2483479321","title":"Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483479321","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483479321?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:17","pubTimestamp":1731669421,"startTime":"0","endTime":"0","summary":"Profit margin: 19% . The move to profitability was primarily driven by higher revenue.NasdaqCM:ENSC Earnings and Revenue History November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates significantly. Earnings per share  also surpassed analyst estimates.Looking ahead, revenue is forecast to grow 148% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 8.6% from a week ago.Be aware that  Ensysce Biosciences is showing  5 warning signs in our investment analysis and 4 of those can't be ignored...","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-third-quarter-2024-111701408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC"],"gpt_icon":0},{"id":"2483538971","title":"This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483538971","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483538971?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:51","pubTimestamp":1731585105,"startTime":"0","endTime":"0","summary":"Key Insights Ensysce Biosciences to hold its Annual General Meeting on 21st of November Salary of US$404.9k is part of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ensc/ensysce-biosciences/news/this-is-why-ensysce-biosciences-incs-nasdaqensc-ceo-compensa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2095319765.USD","LU2210149790.SGD","MNQmain","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NQmain","BK4139","SQQQ","BK4112","QID","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","QLD","NDAQ","IE00B64PRP62.GBP","PSQ","ENSC","TQQQ",".IXIC","BK4585"],"gpt_icon":1},{"id":"2483317408","title":"ENSC Improves Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2483317408","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483317408?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:00","pubTimestamp":1731492000,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  released its 3Q2024 results that showed a much improved cash balance of $4.2 million due in large part to the grant described below and some financial offerings which we have detailed in the past. The company continues to make progress, but notes that future revenue will likely be lower than that seen in 3Q due to the expiration of one grant. Company management also noted that the company’s stock has regained compliance with the NASDAQ stock exchange—a very positive development in our view.Ensysce Biosciences continues to be one of the companies that we cover that we believe most of America would hope is successful and one we are becoming more convinced will achieve its goals. The opioid crisis remains a plague on the American public and is destroying families and entire communities. The National Institute","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensc-improves-position-100000760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","PSQ","QID","QLD",".IXIC","TQQQ","NQmain","SQQQ","MNQmain","BK4139"],"gpt_icon":1},{"id":"2483400512","title":"Ensysce Biosciences GAAP EPS of $0.07 beats by $0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2483400512","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483400512?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:51","pubTimestamp":1731451891,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences press release  (NASDAQ:ENSC): Q3  GAAP EPS of $0.07  beats by $0.24.\nCash and cash equivalents were $4.2 million as of September 30, 2024, compared to $1.1 million as of December 31, 2023.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4282628-ensysce-biosciences-gaap-eps-of-0_07-beats-0_24","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ENSC"],"gpt_icon":0},{"id":"2483050774","title":"Ensysce Biosciences Q3 2024 GAAP EPS $0.07 Beats $(0.29) Estimate, Sales $3.40M Beat $250.00K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050774","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483050774?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:37","pubTimestamp":1731447440,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (NASDAQ:ENSC) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.29) by 124.14 percent.  The company reported quarterly sales of $3.40 million which beat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41920868/ensysce-biosciences-q3-2024-gaap-eps-0-07-beats-0-29-estimate-sales-3-40m-beat-250-00k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ensysce Biosciences Q3 2024 GAAP EPS $0.07 Beats $(0.29) Estimate, Sales $3.40M Beat $250.00K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENSC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-10","symbol":"ENSC","fiscalQuarterEnding":"2024/12","expectedEps":-2.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-2.9},{"market":"US","date":"2024-12-06","symbol":"ENSC","defaultRemindTime":1733495400000,"type":"split","dateTimestamp":1733461200000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-12","symbol":"ENSC","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-08-14","symbol":"ENSC","fiscalQuarterEnding":"2024/06","expectedEps":-0.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.22},{"date":"2024-05-13","symbol":"ENSC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715587200000,"name":null,"time":"Pre-Market","dateTimestamp":1715572800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENSC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENSC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENSC","date":"2025-04-30","current":-0.536584,"percent":0.398069,"low":-1151.871294,"twenty":-1.235122,"median":-0.377888,"eighty":-0.215229,"high":2051.953734,"avg":-10.526218,"sd":300.260769,"marketCap":4285658},"quantilePoints":[{"date":"2021-07-02","current":2051.953734,"twenty":2050.538593,"median":2050.538593,"eighty":2051.387678,"marketCap":353522901},{"date":"2021-07-09","current":1665.538105,"twenty":1670.376702,"median":2037.802329,"eighty":2050.538593,"marketCap":286948898},{"date":"2021-07-16","current":1373.799461,"twenty":1582.794518,"median":1666.827366,"eighty":2047.99134,"marketCap":236686414},{"date":"2021-07-23","current":986.303472,"twenty":1176.265418,"median":1592.804232,"eighty":1966.125264,"marketCap":169926280},{"date":"2021-07-30","current":796.099172,"twenty":905.447974,"median":1416.070215,"eighty":1677.156928,"marketCap":137156742},{"date":"2021-08-06","current":598.835663,"twenty":785.954194,"median":1130.038123,"eighty":1667.600922,"marketCap":103171001},{"date":"2021-08-13","current":462.160228,"twenty":607.289814,"median":986.310516,"eighty":1664.774414,"marketCap":79623737},{"date":"2021-08-20","current":-800.661067,"twenty":514.012352,"median":880.640679,"eighty":1647.936568,"marketCap":79073287},{"date":"2021-08-27","current":-761.364824,"twenty":-747.61113,"median":789.758561,"eighty":1590.301804,"marketCap":75192390},{"date":"2021-09-03","current":-825.221223,"twenty":-767.750462,"median":676.332041,"eighty":1555.901866,"marketCap":81498848},{"date":"2021-09-10","current":-859.605437,"twenty":-780.52174,"median":598.835663,"eighty":1458.340968,"marketCap":84894633},{"date":"2021-09-17","current":-724.524585,"twenty":-780.52174,"median":555.860395,"eighty":1373.799461,"marketCap":71554048},{"date":"2021-09-24","current":-1102.750982,"twenty":-800.661067,"median":488.931707,"eighty":1361.174599,"marketCap":108907687},{"date":"2021-10-01","current":-704.876458,"twenty":-815.397165,"median":-708.560485,"eighty":1130.038123,"marketCap":69613599},{"date":"2021-10-08","current":-582.075678,"twenty":-800.661067,"median":-611.547874,"eighty":1000.40781,"marketCap":57485794},{"date":"2021-10-15","current":-582.075678,"twenty":-788.380994,"median":-604.17982,"eighty":986.317559,"marketCap":57485794},{"date":"2021-10-22","current":-547.691464,"twenty":-781.01294,"median":-601.723805,"eighty":986.303472,"marketCap":54090009},{"date":"2021-10-29","current":-540.32342,"twenty":-780.52174,"median":-596.811776,"eighty":885.234099,"marketCap":53362341},{"date":"2021-11-05","current":-552.603493,"twenty":-778.556926,"median":-582.075678,"eighty":880.640679,"marketCap":54575121},{"date":"2021-11-12","current":-542.779435,"twenty":-776.100911,"median":-575.935642,"eighty":879.231656,"marketCap":53604897},{"date":"2021-11-19","current":-2.041392,"twenty":-776.100911,"median":-559.971547,"eighty":796.099172,"marketCap":38445141},{"date":"2021-11-26","current":-2.034952,"twenty":-774.1361,"median":-555.059508,"eighty":785.954194,"marketCap":38323863},{"date":"2021-12-03","current":-1.609931,"twenty":-769.715274,"median":-550.147479,"eighty":769.891308,"marketCap":30319512},{"date":"2021-12-10","current":-5.705594,"twenty":-764.803244,"median":-542.779435,"eighty":694.367562,"marketCap":107452350},{"date":"2021-12-17","current":-3.812316,"twenty":-763.820838,"median":-539.095413,"eighty":648.151541,"marketCap":71796604},{"date":"2021-12-23","current":-6.594276,"twenty":-762.34723,"median":-537.867406,"eighty":615.743964,"marketCap":124188721},{"date":"2021-12-31","current":-6.053339,"twenty":-758.417601,"median":-6.594276,"eighty":588.690681,"marketCap":114001365},{"date":"2022-01-07","current":-5.138899,"twenty":-754.979176,"median":-6.175695,"eighty":578.5457,"marketCap":96779882},{"date":"2022-01-14","current":-4.224458,"twenty":-753.99677,"median":-5.705594,"eighty":551.774222,"marketCap":79558399},{"date":"2022-01-21","current":-3.078187,"twenty":-753.99677,"median":-5.692715,"eighty":524.720941,"marketCap":57970907},{"date":"2022-01-28","current":-2.150867,"twenty":-750.067147,"median":-5.409367,"eighty":500.767517,"marketCap":40506868},{"date":"2022-02-04","current":-2.073591,"twenty":-736.313461,"median":-5.254814,"eighty":478.223115,"marketCap":39051531},{"date":"2022-02-11","current":-2.073591,"twenty":-719.612556,"median":-4.939267,"eighty":276.652164,"marketCap":39051531},{"date":"2022-02-18","current":-1.39742,"twenty":-709.29729,"median":-4.623721,"eighty":-1.482424,"marketCap":26317336},{"date":"2022-02-25","current":-1.40386,"twenty":-687.68435,"median":-4.456288,"eighty":-1.367797,"marketCap":26438614},{"date":"2022-03-04","current":-1.378101,"twenty":-617.442308,"median":-4.218019,"eighty":-1.378101,"marketCap":25953502},{"date":"2022-03-11","current":-1.416739,"twenty":-611.056671,"median":-4.17294,"eighty":-1.367797,"marketCap":26681170},{"date":"2022-03-18","current":-1.584172,"twenty":-608.600654,"median":-3.915351,"eighty":-1.367797,"marketCap":29834399},{"date":"2022-03-25","current":-1.455377,"twenty":-606.635834,"median":-3.72216,"eighty":-1.378101,"marketCap":27408838},{"date":"2022-04-01","current":-0.909052,"twenty":-605.653428,"median":-3.026669,"eighty":-1.367797,"marketCap":26438614},{"date":"2022-04-08","current":-0.942412,"twenty":-601.723805,"median":-2.640286,"eighty":-1.243923,"marketCap":27408838},{"date":"2022-04-14","current":-0.892372,"twenty":-601.723805,"median":-2.31186,"eighty":-1.109211,"marketCap":25953502},{"date":"2022-04-22","current":-0.884033,"twenty":-599.267791,"median":-2.221704,"eighty":-0.942412,"marketCap":25710946},{"date":"2022-04-29","current":-0.917392,"twenty":-599.267791,"median":-2.189506,"eighty":-0.917392,"marketCap":26681170},{"date":"2022-05-06","current":-0.935552,"twenty":-594.355761,"median":-2.131548,"eighty":-0.917392,"marketCap":27209326},{"date":"2022-05-13","current":-0.797005,"twenty":-582.075678,"median":-2.08647,"eighty":-0.892372,"marketCap":23214444},{"date":"2022-05-20","current":-0.624837,"twenty":-582.075678,"median":-2.073591,"eighty":-0.867353,"marketCap":18199682},{"date":"2022-05-27","current":-0.62899,"twenty":-582.075678,"median":-2.041392,"eighty":-0.82967,"marketCap":18320644},{"date":"2022-06-03","current":-0.645958,"twenty":-578.146055,"median":-2.034952,"eighty":-0.778733,"marketCap":18814863},{"date":"2022-06-10","current":-0.587461,"twenty":-575.198838,"median":-1.960895,"eighty":-0.698325,"marketCap":17111019},{"date":"2022-06-17","current":-0.537744,"twenty":-566.848388,"median":-1.931917,"eighty":-0.663661,"marketCap":15662924},{"date":"2022-06-24","current":-0.547118,"twenty":-561.936359,"median":-1.803122,"eighty":-0.641971,"marketCap":15935954},{"date":"2022-07-01","current":-0.675147,"twenty":-559.971547,"median":-1.758044,"eighty":-0.628942,"marketCap":19665057},{"date":"2022-07-08","current":-0.740288,"twenty":-558.006731,"median":-1.63569,"eighty":-0.63179,"marketCap":21562441},{"date":"2022-07-15","current":-0.73318,"twenty":-554.077102,"median":-1.584172,"eighty":-0.639978,"marketCap":21355409},{"date":"2022-07-22","current":-0.750097,"twenty":-552.603493,"median":-1.526215,"eighty":-0.650372,"marketCap":21848142},{"date":"2022-07-29","current":-0.645214,"twenty":-550.638681,"median":-1.455377,"eighty":-0.648267,"marketCap":18793198},{"date":"2022-08-05","current":-0.542837,"twenty":-547.691464,"median":-1.436058,"eighty":-0.628919,"marketCap":15811251},{"date":"2022-08-12","current":-0.502219,"twenty":-545.726652,"median":-1.416739,"eighty":-0.623627,"marketCap":18104172},{"date":"2022-08-19","current":-0.4432,"twenty":-541.797029,"median":-1.400842,"eighty":-0.597747,"marketCap":15976634},{"date":"2022-08-26","current":-0.437558,"twenty":-540.32342,"median":-1.39098,"eighty":-0.585573,"marketCap":15773232},{"date":"2022-09-02","current":-0.436493,"twenty":-539.341014,"median":-1.39098,"eighty":-0.574176,"marketCap":15734855},{"date":"2022-09-09","current":-0.364844,"twenty":-537.867406,"median":-1.38776,"eighty":-0.560252,"marketCap":13152036},{"date":"2022-09-16","current":-0.333012,"twenty":-537.867406,"median":-1.378101,"eighty":-0.543432,"marketCap":12004543},{"date":"2022-09-23","current":-0.234109,"twenty":-537.376203,"median":-1.352342,"eighty":-0.508327,"marketCap":8439255},{"date":"2022-09-30","current":-0.228893,"twenty":-429.647968,"median":-1.243734,"eighty":-0.498322,"marketCap":8251204},{"date":"2022-10-07","current":-0.234216,"twenty":-6.555638,"median":-1.18844,"eighty":-0.457146,"marketCap":8443092},{"date":"2022-10-14","current":-0.220376,"twenty":-6.367598,"median":-1.109211,"eighty":-0.440474,"marketCap":7944182},{"date":"2022-10-21","current":-0.210262,"twenty":-6.210469,"median":-1.003086,"eighty":-0.435641,"marketCap":7579594},{"date":"2022-10-28","current":-0.250893,"twenty":-6.104857,"median":-0.950752,"eighty":-0.392333,"marketCap":9044283},{"date":"2022-11-04","current":-0.17653,"twenty":-5.98379,"median":-0.934812,"eighty":-0.354113,"marketCap":6363632},{"date":"2022-11-11","current":-0.1248,"twenty":-5.705594,"median":-0.917392,"eighty":-0.266963,"marketCap":4498831},{"date":"2022-11-18","current":-0.202801,"twenty":-5.703018,"median":-0.904882,"eighty":-0.252442,"marketCap":5824224},{"date":"2022-11-25","current":-0.338332,"twenty":-5.692715,"median":-0.892372,"eighty":-0.252314,"marketCap":9716511},{"date":"2022-12-02","current":-0.220875,"twenty":-5.666956,"median":-0.884033,"eighty":-0.252314,"marketCap":6343293},{"date":"2022-12-09","current":-0.218547,"twenty":-5.525282,"median":-0.867353,"eighty":-0.245714,"marketCap":6276429},{"date":"2022-12-16","current":-0.173271,"twenty":-5.293452,"median":-0.82967,"eighty":-0.238048,"marketCap":4976162},{"date":"2022-12-23","current":-0.160808,"twenty":-5.254814,"median":-0.801912,"eighty":-0.234216,"marketCap":4618230},{"date":"2022-12-30","current":-0.167485,"twenty":-5.254814,"median":-0.794791,"eighty":-0.233587,"marketCap":4809988},{"date":"2023-01-06","current":-0.162144,"twenty":-5.208448,"median":-0.777262,"eighty":-0.229014,"marketCap":4656609},{"date":"2023-01-13","current":-0.172083,"twenty":-5.154354,"median":-0.761172,"eighty":-0.22176,"marketCap":4942034},{"date":"2023-01-20","current":-0.151312,"twenty":-4.979194,"median":-0.754483,"eighty":-0.220248,"marketCap":4345527},{"date":"2023-01-27","current":-0.15636,"twenty":-4.713877,"median":-0.749721,"eighty":-0.212142,"marketCap":4490485},{"date":"2023-02-03","current":-0.285115,"twenty":-4.654632,"median":-0.740288,"eighty":-0.212142,"marketCap":8188175},{"date":"2023-02-10","current":-0.319777,"twenty":-4.577355,"median":-0.716973,"eighty":-0.2146,"marketCap":9183632},{"date":"2023-02-17","current":-0.306121,"twenty":-4.487199,"median":-0.704416,"eighty":-0.217004,"marketCap":8791464},{"date":"2023-02-24","current":-0.268404,"twenty":-4.453712,"median":-0.69164,"eighty":-0.21887,"marketCap":7708271},{"date":"2023-03-03","current":-0.278653,"twenty":-4.399619,"median":-0.674554,"eighty":-0.220206,"marketCap":8002622},{"date":"2023-03-10","current":-0.295605,"twenty":-4.221882,"median":-0.670756,"eighty":-0.220476,"marketCap":8489450},{"date":"2023-03-17","current":-0.319044,"twenty":-4.206427,"median":-0.666784,"eighty":-0.220988,"marketCap":9162596},{"date":"2023-03-24","current":-0.28195,"twenty":-4.183244,"median":-0.656993,"eighty":-0.221547,"marketCap":8097283},{"date":"2023-03-31","current":-0.251749,"twenty":-4.160061,"median":-0.645586,"eighty":-0.223101,"marketCap":6085356},{"date":"2023-04-06","current":-0.180809,"twenty":-4.108543,"median":-0.632491,"eighty":-0.22144,"marketCap":4370577},{"date":"2023-04-14","current":-0.203676,"twenty":-3.992628,"median":-0.624837,"eighty":-0.218547,"marketCap":4923327},{"date":"2023-04-21","current":-0.218035,"twenty":-3.838075,"median":-0.616531,"eighty":-0.218035,"marketCap":5270402},{"date":"2023-04-28","current":-0.207399,"twenty":-3.812316,"median":-0.595341,"eighty":-0.211114,"marketCap":5013309},{"date":"2023-05-05","current":-0.186,"twenty":-3.72216,"median":-0.589774,"eighty":-0.207399,"marketCap":4496040},{"date":"2023-05-12","current":-0.170057,"twenty":-3.593365,"median":-0.578926,"eighty":-0.203676,"marketCap":4110665},{"date":"2023-05-19","current":-0.138524,"twenty":-3.078187,"median":-0.574237,"eighty":-0.198975,"marketCap":3519757},{"date":"2023-05-26","current":-0.119818,"twenty":-2.975152,"median":-0.564854,"eighty":-0.195168,"marketCap":3044461},{"date":"2023-06-02","current":-0.12184,"twenty":-2.799991,"median":-0.554475,"eighty":-0.191738,"marketCap":3095845},{"date":"2023-06-09","current":-0.11729,"twenty":-2.663469,"median":-0.544325,"eighty":-0.188162,"marketCap":2980232},{"date":"2023-06-16","current":-0.120324,"twenty":-2.403304,"median":-0.537744,"eighty":-0.185529,"marketCap":3057307},{"date":"2023-06-22","current":-0.110212,"twenty":-2.331179,"median":-0.512831,"eighty":-0.181667,"marketCap":2800390},{"date":"2023-06-30","current":-0.089484,"twenty":-2.31186,"median":-0.504284,"eighty":-0.180301,"marketCap":2273711},{"date":"2023-07-07","current":-0.108696,"twenty":-2.269358,"median":-0.500344,"eighty":-0.179074,"marketCap":2761853},{"date":"2023-07-14","current":-0.095551,"twenty":-2.235871,"median":-0.48602,"eighty":-0.176463,"marketCap":2427861},{"date":"2023-07-21","current":-0.228917,"twenty":-2.222992,"median":-0.463108,"eighty":-0.17453,"marketCap":5816563},{"date":"2023-07-28","current":-0.230007,"twenty":-2.204961,"median":-0.448416,"eighty":-0.176463,"marketCap":5844261},{"date":"2023-08-04","current":-0.212566,"twenty":-2.189506,"median":-0.439793,"eighty":-0.177048,"marketCap":5401094},{"date":"2023-08-11","current":-0.213656,"twenty":-2.17405,"median":-0.436546,"eighty":-0.178163,"marketCap":5428792},{"date":"2023-08-18","current":-0.284273,"twenty":-2.145715,"median":-0.431596,"eighty":-0.17894,"marketCap":5612832},{"date":"2023-08-25","current":-0.281373,"twenty":-2.132836,"median":-0.405938,"eighty":-0.179667,"marketCap":5555558},{"date":"2023-09-01","current":-0.268319,"twenty":-2.119956,"median":-0.373875,"eighty":-0.180213,"marketCap":5297826},{"date":"2023-09-08","current":-0.274121,"twenty":-2.107077,"median":-0.367186,"eighty":-0.180403,"marketCap":5412374},{"date":"2023-09-15","current":-0.255266,"twenty":-2.08647,"median":-0.356221,"eighty":-0.180828,"marketCap":5040094},{"date":"2023-09-22","current":-0.23061,"twenty":-2.083894,"median":-0.35054,"eighty":-0.181286,"marketCap":4553267},{"date":"2023-09-29","current":-0.197251,"twenty":-2.073591,"median":-0.336589,"eighty":-0.182977,"marketCap":3894618},{"date":"2023-10-06","current":-0.159541,"twenty":-2.068439,"median":-0.324381,"eighty":-0.181273,"marketCap":3150059},{"date":"2023-10-12","current":-0.175495,"twenty":-2.047832,"median":-0.319777,"eighty":-0.180154,"marketCap":3465064},{"date":"2023-10-20","current":-0.224808,"twenty":-2.041392,"median":-0.319097,"eighty":-0.180301,"marketCap":4438719},{"date":"2023-10-27","current":-0.15519,"twenty":-2.038816,"median":-0.31805,"eighty":-0.180213,"marketCap":3064148},{"date":"2023-11-03","current":-0.147166,"twenty":-2.034952,"median":-0.312913,"eighty":-0.177994,"marketCap":2905715},{"date":"2023-11-10","current":-0.135455,"twenty":-2.034952,"median":-0.311621,"eighty":-0.175524,"marketCap":2674479},{"date":"2023-11-17","current":-0.234708,"twenty":-2.022073,"median":-0.305807,"eighty":-0.175796,"marketCap":2957311},{"date":"2023-11-24","current":-0.219726,"twenty":-1.970555,"median":-0.300549,"eighty":-0.176418,"marketCap":2768546},{"date":"2023-12-01","current":-0.284645,"twenty":-1.951236,"median":-0.295186,"eighty":-0.17653,"marketCap":3586526},{"date":"2023-12-08","current":-0.245519,"twenty":-1.931917,"median":-0.292717,"eighty":-0.177824,"marketCap":3093536},{"date":"2023-12-15","current":-0.25718,"twenty":-1.931917,"median":-0.287495,"eighty":-0.178672,"marketCap":3240458},{"date":"2023-12-22","current":-0.26467,"twenty":-1.893278,"median":-0.287174,"eighty":-0.179342,"marketCap":3334840},{"date":"2023-12-29","current":-0.25718,"twenty":-1.839184,"median":-0.286889,"eighty":-0.179829,"marketCap":3240458},{"date":"2024-01-05","current":-0.287142,"twenty":-1.800546,"median":-0.286002,"eighty":-0.180183,"marketCap":3617987},{"date":"2024-01-12","current":-0.352061,"twenty":-1.787667,"median":-0.286889,"eighty":-0.180403,"marketCap":4435967},{"date":"2024-01-19","current":-0.29713,"twenty":-1.777363,"median":-0.287142,"eighty":-0.180809,"marketCap":3743830},{"date":"2024-01-26","current":-0.374533,"twenty":-1.738725,"median":-0.287142,"eighty":-0.180905,"marketCap":4719114},{"date":"2024-02-02","current":-0.36954,"twenty":-1.648569,"median":-0.287174,"eighty":-0.181297,"marketCap":4656192},{"date":"2024-02-09","current":-0.294633,"twenty":-1.62281,"median":-0.290994,"eighty":-0.182747,"marketCap":3712369},{"date":"2024-02-16","current":-0.476633,"twenty":-1.609931,"median":-0.289857,"eighty":-0.182811,"marketCap":6005566},{"date":"2024-02-23","current":-0.47931,"twenty":-1.589324,"median":-0.293303,"eighty":-0.183477,"marketCap":6039299},{"date":"2024-03-01","current":-0.49934,"twenty":-1.563565,"median":-0.295134,"eighty":-0.185529,"marketCap":6291674},{"date":"2024-03-08","current":-0.420937,"twenty":-1.537806,"median":-0.29713,"eighty":-0.187269,"marketCap":5303792},{"date":"2024-03-15","current":-0.401657,"twenty":-1.522351,"median":-0.301226,"eighty":-0.187592,"marketCap":5060871},{"date":"2024-03-22","current":-0.539343,"twenty":-1.509471,"median":-0.306121,"eighty":-0.187752,"marketCap":5724083},{"date":"2024-03-28","current":-0.552464,"twenty":-1.475984,"median":-0.311621,"eighty":-0.188069,"marketCap":5863337},{"date":"2024-04-05","current":-0.582158,"twenty":-1.455377,"median":-0.312913,"eighty":-0.188946,"marketCap":6178491},{"date":"2024-04-12","current":-0.520524,"twenty":-1.44765,"median":-0.317056,"eighty":-0.189992,"marketCap":5524363},{"date":"2024-04-19","current":-0.400674,"twenty":-1.43477,"median":-0.319149,"eighty":-0.190623,"marketCap":4252385},{"date":"2024-04-26","current":-0.390727,"twenty":-1.426836,"median":-0.324381,"eighty":-0.191499,"marketCap":4146813},{"date":"2024-05-03","current":-0.406665,"twenty":-1.420036,"median":-0.328965,"eighty":-0.192296,"marketCap":4315962},{"date":"2024-05-10","current":-0.38701,"twenty":-1.416739,"median":-0.333012,"eighty":-0.192744,"marketCap":4107370},{"date":"2024-05-17","current":-0.414034,"twenty":-1.409012,"median":-0.340203,"eighty":-0.194261,"marketCap":4778658},{"date":"2024-05-24","current":-0.386958,"twenty":-1.400239,"median":-0.345309,"eighty":-0.195168,"marketCap":4466149},{"date":"2024-05-31","current":-0.38446,"twenty":-1.397663,"median":-0.35054,"eighty":-0.195327,"marketCap":4437325},{"date":"2024-06-07","current":-0.35929,"twenty":-1.394844,"median":-0.352061,"eighty":-0.195908,"marketCap":4146813},{"date":"2024-06-14","current":-0.348315,"twenty":-1.39098,"median":-0.352127,"eighty":-0.196588,"marketCap":4020141},{"date":"2024-06-21","current":-0.358489,"twenty":-1.39098,"median":-0.352127,"eighty":-0.197251,"marketCap":4137567},{"date":"2024-06-28","current":-0.352192,"twenty":-1.39098,"median":-0.352192,"eighty":-0.197427,"marketCap":4064893},{"date":"2024-07-05","current":-0.295739,"twenty":-1.39098,"median":-0.352061,"eighty":-0.197948,"marketCap":3413327},{"date":"2024-07-12","current":-0.308291,"twenty":-1.39098,"median":-0.35054,"eighty":-0.199037,"marketCap":3558204},{"date":"2024-07-15","current":-0.302639,"twenty":-1.39098,"median":-0.349428,"eighty":-0.199099,"marketCap":3492971},{"date":"2024-08-02","current":-0.303954,"twenty":-1.39098,"median":-0.348315,"eighty":-0.199161,"marketCap":3508142},{"date":"2024-08-09","current":-0.241717,"twenty":-1.387116,"median":-0.345859,"eighty":-0.199565,"marketCap":2789826},{"date":"2024-08-16","current":-0.26447,"twenty":-1.380677,"median":-0.342074,"eighty":-0.199992,"marketCap":2982489},{"date":"2024-08-23","current":-0.307981,"twenty":-1.378101,"median":-0.336589,"eighty":-0.20065,"marketCap":3473180},{"date":"2024-08-30","current":-0.307305,"twenty":-1.370373,"median":-0.334845,"eighty":-0.202073,"marketCap":3465556},{"date":"2024-09-06","current":-0.364516,"twenty":-1.360069,"median":-0.341743,"eighty":-0.202979,"marketCap":4110738},{"date":"2024-09-13","current":-0.306193,"twenty":-1.352342,"median":-0.340037,"eighty":-0.203419,"marketCap":3453020},{"date":"2024-09-20","current":-0.321066,"twenty":-1.320968,"median":-0.335355,"eighty":-0.203676,"marketCap":3620738},{"date":"2024-09-27","current":-0.26527,"twenty":-1.261837,"median":-0.332941,"eighty":-0.20384,"marketCap":2991521},{"date":"2024-10-04","current":-0.225611,"twenty":-1.240811,"median":-0.332086,"eighty":-0.204208,"marketCap":2544273},{"date":"2024-10-11","current":-0.228772,"twenty":-1.222236,"median":-0.329966,"eighty":-0.204208,"marketCap":2579914},{"date":"2024-10-18","current":-0.220531,"twenty":-1.190942,"median":-0.325844,"eighty":-0.204432,"marketCap":2486982},{"date":"2024-10-25","current":-0.387436,"twenty":-1.154623,"median":-0.327156,"eighty":-0.205107,"marketCap":4369210},{"date":"2024-10-31","current":-0.78508,"twenty":-1.119973,"median":-0.329966,"eighty":-0.206243,"marketCap":8853546},{"date":"2024-11-08","current":-0.85568,"twenty":-1.097263,"median":-0.332086,"eighty":-0.207117,"marketCap":9649713},{"date":"2024-11-15","current":-1.112489,"twenty":-1.111833,"median":-0.332941,"eighty":-0.207179,"marketCap":8817483},{"date":"2024-11-22","current":-1.463005,"twenty":-1.187197,"median":-0.335355,"eighty":-0.2074,"marketCap":11595645},{"date":"2024-11-29","current":-1.219747,"twenty":-1.20095,"median":-0.339535,"eighty":-0.207404,"marketCap":9667605},{"date":"2024-12-06","current":-1.19258,"twenty":-1.236427,"median":-0.343222,"eighty":-0.208116,"marketCap":9452284},{"date":"2024-12-13","current":-1.007606,"twenty":-1.236427,"median":-0.346409,"eighty":-0.208205,"marketCap":7986196},{"date":"2024-12-20","current":-1.3089,"twenty":-1.236427,"median":-0.348396,"eighty":-0.208854,"marketCap":10374225},{"date":"2024-12-27","current":-1.541045,"twenty":-1.25409,"median":-0.351152,"eighty":-0.20886,"marketCap":12214182},{"date":"2025-01-03","current":-1.358293,"twenty":-1.336231,"median":-0.352061,"eighty":-0.209,"marketCap":10765705},{"date":"2025-01-10","current":-1.303961,"twenty":-1.349402,"median":-0.352192,"eighty":-0.209431,"marketCap":10335077},{"date":"2025-01-17","current":-1.152491,"twenty":-1.345121,"median":-0.352708,"eighty":-0.209959,"marketCap":9134538},{"date":"2025-01-24","current":-1.307254,"twenty":-1.346768,"median":-0.358489,"eighty":-0.210043,"marketCap":10361175},{"date":"2025-01-31","current":-1.104745,"twenty":-1.338865,"median":-0.359421,"eighty":-0.21027,"marketCap":8756107},{"date":"2025-02-07","current":-1.053706,"twenty":-1.330304,"median":-0.362904,"eighty":-0.210466,"marketCap":8351577},{"date":"2025-02-14","current":-0.996081,"twenty":-1.315486,"median":-0.36403,"eighty":-0.21134,"marketCap":7894850},{"date":"2025-02-21","current":-0.926932,"twenty":-1.3089,"median":-0.364942,"eighty":-0.212244,"marketCap":7346778},{"date":"2025-02-28","current":-0.864368,"twenty":-1.307254,"median":-0.367373,"eighty":-0.212536,"marketCap":6850903},{"date":"2025-03-07","current":-0.856136,"twenty":-1.303961,"median":-0.371707,"eighty":-0.212566,"marketCap":6785656},{"date":"2025-03-14","current":-0.637359,"twenty":-1.279265,"median":-0.374533,"eighty":-0.212566,"marketCap":5090547},{"date":"2025-03-21","current":-0.626307,"twenty":-1.273906,"median":-0.375127,"eighty":-0.213521,"marketCap":5002277},{"date":"2025-03-28","current":-0.548899,"twenty":-1.249136,"median":-0.377888,"eighty":-0.213656,"marketCap":4384018},{"date":"2025-04-04","current":-0.402877,"twenty":-1.247983,"median":-0.38361,"eighty":-0.213683,"marketCap":3217756},{"date":"2025-04-11","current":-0.330747,"twenty":-1.243734,"median":-0.377888,"eighty":-0.213752,"marketCap":2641651},{"date":"2025-04-17","current":-0.330747,"twenty":-1.241359,"median":-0.377888,"eighty":-0.214536,"marketCap":2641651},{"date":"2025-04-25","current":-0.582325,"twenty":-1.237295,"median":-0.37685,"eighty":-0.214732,"marketCap":4650993},{"date":"2025-04-30","current":-0.536584,"twenty":-1.235122,"median":-0.377888,"eighty":-0.215229,"marketCap":4285658}],"updateTime":1746102641427}}}